Classifications

• • B—PERFORMING OPERATIONS; TRANSPORTING
  • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
  • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
  • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
  • B01J13/02—Making microcapsules or microballoons
  • B01J13/06—Making microcapsules or microballoons by phase separation
  • B01J13/14—Polymerisation; cross-linking
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
  • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis

Definitions

• This invention relates to nanocapsules and a method for their preparation.
• U.S. Pat. No. 4,931,362 describes a method of forming microcapsules or micromatrix bodies having an interior water-immiscible liquid phase containing an active, water-immiscible ingredient.
• an organosilicon compound is used as a capsule-forming or matrix-forming monomer.
• Microcapsules prepared by a sol-gel process are also disclosed in GB2416524, US6855335, WO03/066209. Such microcapsules have use in various applications where chemical contact between the active ingredient and the immediate environment should be nimimized, e.g. colorants for cosmetics, food colors, sunscreen compositions or in other applications where delivery of the active ingredient is of benefit (e.g. topical delivery onto the skin).
• nanocapsules particularly having a narrow size distribution, which are inert, simplified in production, can be easily incorporated in various carriers, which are capable of isolating and/or releasing the active ingredient therefrom, depending on the intended use, and yet which are physically stable during storage (e.g. do not form agglomerates, preferably do not form agglomerates even in compositions substantially free of surfactants) thereby providing long term use of the formulation.
• FIG. 1 shows particle size distribution of the nanocapsules measured by dynamic light scattering obtained by Example 1 (Fig. IA) and Example 2 (Fig. IB).
• Fig 2 shows the nanocapsules obtained according to example 2 analyzed by transmission electron microscope (TEM).
• Fig 2a shows that the particles obtained are in the nanometric range and
• Fig. 2b shows a clear core-shell structure.
• a process for preparing nanocapsules having a core-shell structure comprising:
• a composition comprising nanocapsules as described in the present invention, and a carrier.
• the present invention is based on the finding that it is possible to prepare by a sol-gel process nanocapsules having a metal oxide shell, which are characterized by narrow particle size distribution.
• Such nanocapsules are advantageous for applications where narrow size distributions in the nano-scale size are of benefit such as for incorporation into fibers (e.g for use in textile), dispersion in matrices (such as UV stabilizers of polyolefin matrices), cosmetics, and pharmaceutical applications (e.g. parenteral administration).
• the nanocapsules obtained were found to be physically stable during storage (in an aqueous medium free of surfactants) and did not undergo agglomeration.
• the present invention relates to a process for preparing nanocapsules having a core-shell structure, comprising: (a) preparing an oil-in-water emulsion by emulsification of an oily phase that comprises a core material, in an aqueous phase, under high shear forces, wherein one or both of the oily phase, and the aqueous phase comprises a sol-gel precursor;
• dlO 10-80 nm
• d50 30- 200 nm
• d90 70-500 nm, in diameter.
• nonocapsules prepared by a sol-gel process, having a narrow particle size distribution and yet which are physically stable (e.g. which do not form agglomerates) by a process utilizing high shear forces and high pressure homogenization.
• core material refers to the material constituting the inner part (core) of the nanocapsules optionally comprising an active ingredient.
• the core material is surrounded by the shell of the nanocapsules.
• This term refers to any material present in the core, e.g. both the active ingredient and the excipients such as the liquid carrier, or the excipients in case an active ingredient is absent. This term will also
• the core material may include as an excipient a liquid hydrophobic core material e.g. oils.
• the oils may be cosmetically acceptable (depending on the intended
• 15 application and may be for example alkanes, alkenes, glycerides or triglycerides, fatty alcohols, fatty acids and fatty acids esters like dicaprylyl maleate, Capric triglyceride, caprylic triglyceride, octyl palmitate, C 12 -C 15 alkyl benzoate, dioctyl maleate, dioctyl malate, propylene glycol dicaprylate, propylene glycol dicaprate, diisopropyl adipate, hexyl laurate, lanolin, natural or synthetic oils and waxes, and mixtures thereof. It is
• high shear forces energy applied by mixers or disperses in order to transport one phase (oily phase) into a main continuous phase (aqueous phase), with which it would normally be immiscible to obtain an emulsion,
• the high energy dispersing process can be conducted by high shear mixing or by high energy milling. This phase transport is accomplished by an input of energy, usually through high speed dispersing units such as an electric motor and rotating propeller or high speed rotor. Preferably the high speed dispersing units work at a shearing rate in the range of 0.1 —
• the particle size also depends on the type of oil used in the preparation of the emulsion.
• high pressure homogenization refers to the creation of a high concentration of energy which is released on the processed emulsion. This high pressure (energy) creates a number of fluid mechanical effects like cavitations, turbulence, shear and impact which result in a homogeneous nano-droplet size distribution.
• the process may be carried out through a valve (homogenizing valve) or by milling cells, with application of a pressure, typically in the range of 1000-2000 bar, preferably 1300-1700 bar.
• An example of high pressure homogenizer is Microfluidizer.
• homogenizing the emulsion may be conducted by high shear homogenizer (Polytron PT 6100 Kinematica) with dispersing aggregates PT-DA 6045/6 in 1000-4000rpm (preferably 3000 rpm) for about 1-10 min (preferably about 5 min).
• the dispersion is then homogenized in a high pressure homogenizer (e.g. M-I lOY microfluidizer processor (Microfiuidics) for about 5-30 min (preferably about 10 min).
• a high pressure homogenizer e.g. M-I lOY microfluidizer processor (Microfiuidics) for about 5-30 min (preferably about 10 min).
• the terms dlO, d50 and dPO relate to the diameter of 10%, 50% and 90% by volume of the particles, respectively.
• the designation dlO 10-80 ran, indicates that 10% by volume of the particles (i.e. the nanocapsules) have a diameter less than or equal to a value within the indicated range of 10 to 80 nm.
• the designation d50 ⁇ 30-200 nm means that 50% by volume of the particles have a diameter less than or equal to a value within the range of 30 to 200 nm;
• the difference between d90 and dlO is preferably in the range 50-300nm, more preferably in the range 50-250nm, even more preferably in the range 50-200nm, and most preferably in the range 50-150nm.
• Particle size distribution by volume is typically measured by methods such as light scattering (e.g. dynamic light scattering) or laser diffraction.
• the emulsion in step (a) is characterized by having a median particle (droplet) size diameter (d50) in the range 1-10 ⁇ m.
• dlO 0.5-5 ⁇ m
• dlO 0.5-5 ⁇ m
• d50 1-10 ⁇ m
• 50% by volume of the particles (droplets) size (in diameter) is less than or equal to a value in the rangel-10 ⁇ m.
• d90 2-30 ⁇ m
• 90% by volume of the particles (droplets) size (in diameter) is less than or equal to a value in the range 2-30 ⁇ m.
• the oily phase comprises the sol-gel precursor.
• step (a) comprises
• sol-gel precursor refers to any organo-metallic or organo semi-metalic monomer, or a prepolymer (which means several monomers polymerized together) thereof, which allows to obtain a metal oxide material (e.g. silica) by in-situ polymerization (an inorganic sol-gel polymerization process).
• a metal oxide material e.g. silica
• in situ polymerization refers to the sol-gel polymerization process of a sol-gel precursor forming an inorganic polymer at the oil- water interface of the emulsion as a result of the hydrolysis and condensation reactions of the sol-gel precursor.
• the sol-gel precursors are selected from metal alkoxide monomers, semi-metal alkoxide monomers, metal ester monomers, semi-metal ester monomers and from monomers of the formula M(R) n (P) ra , wherein M is a metallic or semi metallic element, R is a hydrolysable substituent, n is an integer from 2 to 6, P is a non polymerizable substituent and m is and integer from 0 to 6, a partially hydrolyzed and partially condensed polymer thereof, or any mixture thereof.
• the metallic or semi metallic element is selected from Si, Ti, Zr, Al, and Zn.
• R i.e. the hydrolysable substituent
• R is selected from an d-Qalkoxy, an aryloxy, a carboxylic ester, an acyloxy group, a halo (e.g. chloro or bromo).
• C] . -C 6 alkoxy is meant that the alkyl of the alkoxy is a C 1 -C 6 alkyl, more preferably C 1 -C 4 alkyl and most preferably a methyl or ethyl.
• the aryl of the aryloxide is a phenyl group.
• P i.e. the non polymerizable substituent
• non polymerizable substituenf is meant that said non polymerizable substituent does not undergo hydrolysis (i.e. in the M-P bond) in the conditions used to prepare the nanocapsules (i.e. the sol-gel process conditions used to prepare the nanocapsules' shell).
• the non polymerizable substituent does not undergo polymerization in the conditions used to prepare the nanocapsules (i.e. the sol-gel process).
• the sol-gel precursor may be a single monomeric unit or alternatively the sol- gel precursor may be comprised of a number of monomeric units (at times also referred to as "prepolymer").
• the precursor may be an oligomer of the precursor for example, a prehydrolyzed tetraethoxy silane (TEOS) which is based on the hydrolysis of TEOS 5 which may be used in order to obtain short chain polymers (prepolymer) that can also be used for encapsulation.
• TEOS tetraethoxy silane
• the sol-gel precursors are selected from silicon alkoxide monomers, silicon ester monomers, monomers of the formula Si(R) ⁇ (P) m , where R is a hydrolysable substituent, n is an integer from 2 to 4, P is a non polymerizable substituent and m is and integer from 0 to 2, a partially hydrolyzed and partially condensed polymer thereof, and any mixture thereof.
• R and P may be as defined above.
• R is a C 1 -C 6 alkoxy, more preferably C 1 -C 4 alkoxy, and most preferably R is an ethoxy or methoxy group.
• the precursor is selected from metal alkoxide monomer, semi metal alkoxide monomer, a partially hydrolyzed and partially condensed polymers thereof, and any mixture thereof.
• the semi metal alkoxide monomer is silicon alkoxide monomer.
• the silicon alkoxide monomer is selected from tetramethoxy silane (TMOS), tetraethoxy silane (TEOS), and mixtures thereof.
• TMOS tetramethoxy silane
• TEOS tetraethoxy silane
• the silicon alkoxide monomer is tetraethoxy silane.
• sol-gel precursors which may be used in the present invention (termed also sol-gel precursors) are also described in US Patent Nos. 6,303,149, 6,238,650,
• step (c) comprising adding a catalyst to accelerate the formation of the nanocapsular shell for example, by adding an acid or a base.
• step (c) comprising adding a catalyst selected from an acid or base.
• a catalyst selected from an acid or base.
• the acid is added to provide the nano-emulsion a pH in the range 2-5.
• a base is added to provide the nano-emulsion a pH in the range 8-13.
• the conditions in step (c) may comprise for example mixing and stirring the nano emulsion with another aqueous solution at a suitably selected pH in the range of 2-13, preferably to obtain a pH of 2-5 or 8-13 of the nano-emulsion, more preferably to obtain a pH of 2-5 of the nano-emulsion, even more preferably a pH of 3-4, so as to form nanocapsules in a suspension.
• the pH of the aqueous solution is in the range of 2-5, even more preferably 3-4.
• the pH of the aqueous phase in step (a) may be in the range 2-13.
• the pH of the aqueous phase in step (a) may be in the range 2-5.
• the conditions in step (c) may be allowing nanocapsules formation (without adding a catalyst) optionally with stirring until nanocapsules are formed.
• the pH of the aqueous phase in step (a) is in the range of 5-8.
• nanocapsules in suspension maybe obtained after the nano-emulsification step without the need of further processing, e.g. adding a catalyst such as an acid or base.
• the conditions in step (c) may be allowing nanocapsules formation (with optionally mixing of the nano-emulsion) without further treatment to accelerate hydrolysis and polycondensation.
• the conditions in step (c) comprise mixing the nano-emulsion.
• the mixing in step (c) may be conducted for at least 4 hours, typically 4-24 hours.
• An indication for the completion of the reaction and nanocapsules' formation is obtaining constant loss on drying value, upon repeated measurements of samples of the nanocapsules taken form the reaction medium.
• one of the aqueous phase, oily phase, or both includes a surfactant.
• the aqueous phase in step (a) includes a surfactant.
• the process may further comprise adding a catalyst in step (a).
• the process may further comprise the step of adding an ingredient selected from a surfactant, a catalyst, and a mixture thereof in step (a).
• the surfactant may be selected from a cationic surfactant, an anionic surfactant, a non-ionic surfactant and mixtures thereof.
• the surfactant is a cationic surfactant.
• the cationic surfactant is cetyltrimethyl ammonium chloride (CTAC).
• the catalyst is an acidic solution such as a hydrochloric acid solution, phosphoric acid solution or nitric acid solution.
• the catalyst may also be a salt like sodium fluoride (NaF), ammonium fluoride, and mixtures thereof.
• NaF sodium fluoride
• the hydrophobic oily phase and/or the aqueous phase may include additional surfactants or any additives to improve the product.
• the surfactant may be for example an anionic surfactant, a cationic surfactant, a non-ionic surfactant, an anionic polymeric surfactant, a cationic polymeric surfactant, a non-ionic polymeric surfactant, or mixtures thereof.
• the emulsification may be performed using at least one emulsification agent
• the aqueous solution may comprise at least one hydrophilic (water soluble) surfactant.
• the oily phase may comprise a hydrophobic surfactant, hydrophobic polymeric surfactant, or mixtures thereof.
• a hydrophobic surfactant or hydrophobic polymeric surfactant is a non-ionic surfactant.
• the hydrophilic surfactant may be for example an anionic, a cationic, a non- ionic surfactant, or mixtures thereof.
• the emulsification is preferably performed using at least one hydrophilic surfactant.
• the hydrophilic surfactant is a cationic surfactant.
• Mo st preferably the cationic surfactant is cetyltrimethyl ammonium chloride (CTAC).
• the concentration of the cationic surfactant in the aqueous solution (aqueous phase) may be from 0.1 to 5% (w/w) and more preferably from 1 to 5% (w/w). It is appreciated that the concentration of the surfactant will also depend on the percentage of the oily phase and aqueous phase. The concentration of the surfactant may be 5 — 10
• the process of the present invention may further comprise the step of isolating and rinsing the nanocapsules through procedures selected from at least one of: separation by centrifuge; filtration; evaporation; re-suspension in_an aqueous medium; and dialysis.
• the process of the present invention may further comprise an additional step of isolating and rinsing the nanocapsules through cycles selected from separation by centrifuge or by filtration and re-suspension in water, evaporation and re- suspension in water or by dialysis or by any other conventional means known in the art.
• the suspension so obtained may be stabilized by adding additives such as non- ionic, cationic or anionic polymers or surfactants or mixtures thereof.
• the suspension may be stabilized by any other suitable suspending agent to obtain the final product in a suspension form.
• the process may further comprise the step of removing the water (such as evaporation filtration etc.) to obtain the final product (nanocapsules) in a powder form.
• the process may further comprise the step of adding-reconstitution additives such as non-ionic, cationic or anionic surfactants or polymers, or mixtures thereof.
• the surfactants or polymers maybe non-ionic, cationic or anionic. It has been surprisingly found that the nanocapsules of the present invention are physically stable for a period of time of three months, in an aqueous medium substantially free of surfactants, at ambient conditions, with an increase of about 10% in particle size parameters (dlO, d50, d90).
• substantially free of surfactants is meant that only negligible amount of surfactant originating from the emylsification process (used in preparation of the emulsion) may be present.
• the nanocapsules are physically stable in a liquid or semi-solid composition for a period of 3 month, more preferably for 1 year (preferably for 3 months to one year) and most preferably for 3 years (preferably 3 months to 3 years), at ambient temperature.
• the composition is substantially free of surfactant.
• physically stable is meant an increase of up to 30% in diameter, preferably up to 20% and more preferably up to 10% of the parameters dlO, d50, and d90.
• Step (a) is preferably carried out at a temperature of 20-25 0 C;
• step (b) is preferably carried out at a temperature of 5-25 0 C, more preferably 5-15 0 C, even more preferably 5-10 0 C;
• Step (c) is preferably carried out at a temperature of 4-35 0 C, more preferably 15-25 0 C.
• the nano-emulsion obtained in step (b) and/or the nanocapsules obtained in step (c) may further comprise an additional step selected from: heating, cooling, subjecting to vacuum or pressure, keeping under inert gas atmosphere, subjecting to changes in pH, and subjecting to an aging period.
• the term “aging” refers to the period of time added over the end of the nanocapsular shell (metal oxide-shell) formation, needed in order to obtain the smallest leaching rate of the active ingredient due to closure of the open pores of the shell.
• the product obtained by the process is a suspension of said nanocapsules.
• the product obtained is a powder of said nanocapsules.
• the process further comprises a further step of removing the water by any means known in the art such as evaporation, filtration, freeze drying etc.
• the process may further comprise the step of dispersing the obtained nanocapsules in a carrier.
• the carrier may be for example a cosmetic carrier, a pharmaceutical carrier, a food carrier, a carrier used in agriculture or industrial processes.
• the carrier may be for example a liquid, a semi solid or a solid carrier.
• Incorporation of the final product either in the form of a suspension or a powder in cosmetic or pharmaceutical formulations can improve the bioavailability of the cosmetic or pharmaceutical actives ingredients thus retaining a reservoir of active ingredients to prolong duration of action.
• the process of the present invention may further include the step of modifying the surface charge of the products by adding anionic or cationic surfactants or polymers during any step of the process.
• the emulsion obtained in step (a) and/or the nano emulsion obtained in step (b) may be heated or cooled, subject to vacuum, or pressure, or kept under inert gas atmosphere, subject to changes in pH, or subject to an optional further aging period at room or accelerated temperature.
• the resulting particles can be optionally isolated and rinsed through cycles of centrifuge or filtration and re-suspension in deionized water or by dialysis or by any other technique known in the art.
• the obtained suspension may be incorporated for example into a suitable carrier.
• the final product may also be used in a powder form, after removal of the water by appropriate means (such as drying, lyophilization, etc.) with optional addition of reconstitution additives such as non-ionic, cationic or anionic surfactants or polymers.
• the concentration of the oily phase in the emulsion may be in the range 5% to 80% (w/w), more preferably in the range 10-60%.
• the weight ratio of the sol-gel precursors to the core material is from
• the weigh ratio of the sol-gel precursors to the core material is from 15/85 to 70/30.
• the above ratios relate to tetraethoxy silane (TEOS) as a precursor.
• TEOS tetraethoxy silane
• the weight ratios when using other precursors can be calculated on mole basis.
• the concentration of the core material based total weight of the nanocapsules may be from 20% to 98% (w/w). According to a specific embodiment the concentration of the core material based total weight of the nanocapsules is from 50% to 95% (w/w).
• the core of the nanocapsules obtained is a liquid core. More preferably the liquid core is an oily core for example in the form of a solution, suspension or dispersion.
• the oily phase comprising the sol-precursor and the core material (including the active ingredient) are water immiscible.
• the sol-gel precursor and the core material are mixed before emulsification.
• the core material is emulsified in an aqueous phase to which a sol-gel precursor was added (before or after emulsification).
• the active ingredient may be any molecule or substance that is soluble or that can be suspended in the sol-gel precursor (metal or in the semi metal alkoxides) of choice.
• the nanocapsular shell formed comprises at least one metal oxide comprising polymerized sol-gel precursors obtained by in-siru polymerization of the sol-gel precursors.
• the core of the nanocapsules in accordance with the present invention is preferably substantially free of the metal oxide which originates from the sol-gel precursor (as residual impurity). Further, the metal oxide shell is preferably substantially free of the core material constituents (as residual impurity). By the term “substantially free” is meant that the residual impurity has a concentration (w/w) of up to 10% (w/w), preferably up to 5% (w/w), more preferably up to 1% (w/w) even more preferably up to 0.5% (w/w).
• the core material comprises at least one active ingredient.
• active ingredient refers to any molecule or substance that can be used in agriculture, industry (including food industry), medicine, cosmetics, and which grants the final product (cosmetics, drug, etc.) at least one desired property.
• nanocapsules according to the present invention may be useful for oral administration, parenteral administarion (e.g. intravenous, intramuscular, subcutaneous), topical administration, ophthalmic administration, etc.
• parenteral administarion e.g. intravenous, intramuscular, subcutaneous
• topical administration e.g. topical administration
• ophthalmic administration e.g. topical administration
• the core material consists essentially of at least one active ingredient.
• the term "consists essentially of at least one active ingredient” means that the core material comprises a high percentage (w/w) of an active ingredient and low percentage of excipients (such as the liquid carrier).
• concentration of the active ingredient based on the total weight of the core material is above 80% w/w, more preferably above 90% w/w and most preferably above 95% w/w.
• the term "consists essentially of an active ingredient” also means that the core material may also include excipients which are needed for the preparation of the nanocapsules or to dissolve the active ingredient.
• concentration of the excipients based on the total weight of the core material is up to 20% w/w, more preferably up to 10% w/w and most preferably up to 5% w/w.
• the core material is said at least one active ingredient (i.e. does not include excipients such as a liquid carrier).
• the active ingredient is an oil such as a sunscreen agent and additional excipients such as solvents or co-solvents are not needed in order to prepare the oily phase of the emulsion described in the process below
• the core material of the formed nanocapsules is the active ingredient.
• the core material comprises an excipient preferably an oily solvent and the active ingredient (dye).
• the core is a liquid core and more preferably the liquid core is an oily core (i.e. a non-aqueous water immiscible liquid).
• the liquid core, preferably oily core may be for example in the form of a solution, suspension or dispersion.
• the active ingredient may be present in a dissolved, dispersed or suspended form in the core (i.e. the active ingredient may be present in a dissolved, dispersed or suspended form in the excipients used to prepare the core material of the nanocapsules).
• the nanocapsules may be useful for cosmetic or pharmaceutical applications.
• the nanocapsules may also be used in agricultural, polymeric or food industry.
• the nanocapsules may be useful for any application wherein the active ingredient should be isolated, temporarily or permanently from the ambient surroundings.
• the active ingredient may be any molecules or substances that are soluble or that can be suspended in the sol-gel precursor (metal or the semi metal alkoxides) of choice.
• the active ingredient may be for example sunscreen agents, dental agents, fragrances, perfume, colors and dyes, food colors and food additives, waxes, antioxidants, humidifiers, vitamins, pesticides, biological molecules (such as enzymes, co-en2ymes or antibodies), drugs, catalysts, reagents or mixtures thereof.
• the drugs may be for example dermatological agents, anti-inflammatory agents, analgesics, anti-fungal agents, antibiotics, anti-viral agents, anti-acne agents, anti histamines, skin whitening agents, anti-parasitic agents, muscle relaxants, steroids, hormones, astringents or mixtures thereof.
• the active ingredient may be for example a pesticide such as insecticides, herbicides or fungicides used in agriculture or industry.
• the active ingredient may be a sunscreen agent.
• the sunscreen agent may be for example a UVA absorber, a UVB absorber, or mixtures thereof.
• the UVA absorber may be for example octylmethoxy cinnamate, p- aminobenzoic acid, or mixtures thereof.
• the UVB absorber may be for example 3-butylmethoxydibenzoyl methane, benzophenone-3 or mixtures thereof.
• the sunscreen agent (ultra-violet absorbing molecules or ultra-violet reflecting substances) may be, for example, octylmethoxy cinnamate, 3-butylmethoxydibenzoyl methane, benzophenone-3, benzophenone-1, benzophenone-2, benzophenone-6, benzophenone-4, benzophenone-8, 2-ethylhexyl p-methoxycinnamate, p-arninobenzoic acid, 2-ethylhexyl N, N-dimethyl-p-aminobenzoate, 2-cyano-3, 3-diphenylacrylic acid 2-ethylhexyl ester, 2-ethylhexyl-2-cyano-3,3-diphenylacrylate, oxybenzone, 2- phenylbenzimidizole-5-sulfonic acid, homomenthyl salicylate, octyl salycilate, 4,4'- meth
• the active ingredient may be for example natural food colors or synthetic food colors or food additives used in food products or oral drugs.
• the active ingredient may be for example natural food colors or synthetic food colors used in cosmetic colors and skin applications. According to one preferred embodiment the active ingredient is a dye.
• the active ingredient may be for example a dye such as a fluorescent dye.
• the fluorescent dye may be used in cosmetics, pharmaceutics, inks or any other industries where it is necessary to avoid the contact of the dye with its dispersing environment or with the different organs of the human body (such as the skin).
• the fluorescent dye may be for example nile red, perylene, pyrene, antracene, or mixtures thereof.
• the nano-emulsion particle size distribution obtained in (b) is similar to the particle size distribution of the nanocapsules.
• the particle size distribution (dlO, d50, d90) of the nono-emulsion may have the same values as indicated in the present invention with respect to the nanocapsules.
• the process further comprising chemically modifying the surface of the metal oxide shell.
• alkyl group may contain 1 carbon atom, 2 carbon atoms, 3 carbon atoms, etc., up to and including 18 carbon atoms.
• the C 1 -C 1S aIkVl is a C 1 -C 6 alkyl (e.g. methyl, ethyl, propyl etc.).
• the Ci-Cisalkyl methacrylate may be for example methyl methacrylate, ethyl methacrylate, propyl methacrylate, etc.
• the aryl may be for example a phenyl or benzyl.
• the halo group may be for example chloro, fluoro, etc.
• the carboxy C 1 -C 1S aIkVl may be for example carboxymethyl, carboxyethyl, carboxypropyl, etc.
• the cycloalkyl in the epoxycycloalkyl_ may be a 5-6 membered ring, such as epoxycyclopentyl or epoxycyclohexyl.
• the glycidoxyQ-Qsalkyl may be for example glycidoxypropyl.
• OR is preferably selected from CrC ⁇ alkoxy, an aryloxy, a carboxylic ester, an acyloxy group, a halo (e.g. chloro or bromo).
• R 1 , R 2 , R 3 preferably does not undergo hydrolysis in the conditions used to conduct the chemical modification of the metal oxide surface.
• Such surface modification with functional groups R , R , R is preferably carried out by a further step comprising: reacting the nanocapsules obtained in step (c) with a precursor as defined above in an aqueous medium having a pH in the range of 2-7, more preferably 2-4.
• the reaction is preferably mixed (e.g. by mechanical stirring or magnetically stirring) for a period of e.g. 4-24 hours.
• An indication for the completion of the reaction can be obtained by constant loss on drying measurements_of a sample of the nanocapsules taken at various time intervals.
• the invention additionally relates to product obtained by the process as described in the present invention.
• the difference between d90 and dlO is preferably in the range 50-300nm, more preferably in the range 50-250nm, even more preferably in the range 50-200nm, and most preferably in the range 50-150nm.
• the core material comprises at least one active ingredient.
• the active ingredient is selected from suncscreen agents, dental agents, fragrances, perfume, colors and dyes, food colors, food additives, waxes, antioxidants, humidifiers, vitamins, pesticides, biological molecules, drugs, catalysts, reagents, and mixtures thereof.
• the metal oxide is selected from silica, titania, alumina, zirconia, ZnO.
• functional groups selected from from from C 1 -C 1S aI-CyI, aryl, aryl C 1 -C 1S aIlCyI amine, CrQgalkyl methacrylate, haloC
• nanocapsules constituents concentrations of the constituents, specific active ingredient, and other parameters and characteristics may be as described in the present invention with respect to the process, product obtained by the process, etc.
• the invention additionally relates to a composition comprising nanocapsules as described in the present invention and a carrier.
• the nanocapsules of the present invention may be useful for human or non- human applications, as they may be easily incorporated in various carriers.
• the nanocapsules may be easily dispersed or suspended in a carrier or diluent.
• Simple mixing with any suitable mixer or stirrer is sufficient to achieve an effective dispersion. If necessary, due to the small particle size distribution of the nanocapsules, high shear forces may be applied to facilitate fast and efficient mixing of the nanocapsules in the carrier.
• the composition may be for example a cosmetic composition, a pharmaceutical composition, a food composition, a composition used in agriculture or industrial processes.
• the carrier may be a cosmetic carrier, a pharmaceutical carrier, a food carrier, a carrier used in agriculture or industrial processes.
• the carrier may be a liquid, a semi solid or a solid carrier.
• the carrier may be for example an emulsion, a cream, an aqueous solution, an oil, an ointment, a paste, a gel, a lotion, a milk, a suspension, a powder, a processed food , a spray, a paint, a lacquer, a coating, a plastic or a detergent.
• the carrier may further comprise at least one non-encapsulated active ingredient.
• the final form of the composition may be for example an emulsion, an aqueous solution, an oil, a semi- solid formulation (such as a cream, an ointment, a paste, or a gel), a lotion, a milk, a suspension, a powder, a capsule, an aerosol, a spray, a foam, a shampoo, a hair conditioner, a lacquer, a makeup, a solid stick, a toothpaste, a food, a paint, a plastic or a coating.
• a semi- solid formulation such as a cream, an ointment, a paste, or a gel
• a lotion such as a cream, an ointment, a paste, or a gel
• a lotion such as a cream, an ointment, a paste, or a gel
• a lotion such as a cream, an ointment, a paste, or a gel
• a lotion such as a cream, an oint
• the composition is a suspension of said nanocapsules in an aqueous medium.
• the suspension comprises low surfactants concentration based on the nanocapsule's weight.
• low surfactants concentration based on the nanocapsule's weight is meant a concentration of preferably up to 5%w/w, more preferably up to 2%w/w and most preferably up to 0.5%w/w based on the total weight of the nanocapsules.
• the composition is a suspension of said nanocapsules in an aqueous medium substantially free of surfactants.
• the suspension is physically stable for a period of at least 3 month, preferably for 1 year and more preferably for 3 years, at ambient temperature.
• the composition is a dispersion of the nanocapsules in a liquid or semi-solid carrier and said composition is physically stable for a period of at least 3 month, preferably for 1 year and more preferably for 3 years, at ambient temperature.
• the composition may be substantially free of surfactants.
• the composition may comprise low surfactants concentration based on the nanocapsule's weight.
• physically stable is meant an increase of up to 30%, preferably up to 20%, more preferably up to 10% and most preferably up to 5%, in dlO, d50, and d90 parameters.
• compositions of the present invention may be applied topically.
• topical application refers to an application on the skin, hair, mucous membranes, rectal application, nasal application, as well as dental application within, the oral cavity.
• the release of the active ingredient from the nanocapsules can be designed to be immediate, delayed, or controlled; this can be controlled by varying the composition of the nanocapsular shell, its diameter, and by varying the composition of the carrier surrounding the nanocapsules.
• Release can. be obtained and controlled by aging time, thermal treatment ⁇ or any mechanical mean that can change the characteristic porosity or strength of the shell, or by chemical means such as organic polymers and/or surfactants that may be added while the nanocapsules are being formed, to control the surface nature of the shell and the rate of diffusion through the pores.
• one active ingredient can be encapsulated while a second active ingredient can be present in the carrier that surrounds the nanocapsules. This is advantageous when the ingredients acts synergistically together, yet one is chemically reactive with another.
• each of the active ingredients may be nano-encapsulated in separate nanocapsules.
• Hie active ingredient may be encapsulated alone, or with other ingredients within the same nanocapsule.
• Co-encapsulation of compounds that enhance stability of the sensitive ingredient is beneficial.
• anti oxidants can be co- encapsulated with oxygen-sensitive or oxidant-sensitive ingredients, to provide "localized protection".
• Example Ia nanometric core shell particles of paraffin oil
• Examplelb nanometric core shell particles of IPM (isopropylmyristate)
• Nile Red 0.02g was dissolved in 2Og paraffin oil by heating (to a temp of 60 0 C) and stirring for 30min. 2Og of TEOS were added to the hot solution and the mixture was stirred for another 30min. The bright orange solution was cooled to room temperature. A solution of 0.5 — 2% w/w of CTAC was prepared. The oil phase and the CTAC solution were homogenized using a high shear homogenizer (Polytron PT 6100 Kinematica) with dispersing aggregates PT-DA 6045/6 in 3000 rpm for about 5 min in a long neck beaker (200ml). During homogenization the emulsion color has changed from bright orange to purple.
• a high shear homogenizer Polytron PT 6100 Kinematica
• the emulsion was sheared for lOrnin. in M-IlOY microfluidizer processor (microfluidics) at a temp of 7 0 C to obtain nano-emulsion.
• 150g RO (reverse osmosis) water was added and the emulsion was sheared for additional 5min.
• the nano-emulsion was transferred to a 400ml beaker equipped with magnetic stirrer.
• 0.5ml of IM HCl solution were added as catalyst and the nano- emulsion was stirred for 24h to form nanometric capsules having a core/shell structure.
• PSD particle size distribution
• the nanometric core-shell particles were analyzed by transmission electron microscope (TEM) as seen in the pictures shown in Fig. 2.
• Fig. 2a shows the nanocapsules obtained.
• a core shell structure of the nanometric particles can be observed having a silica shell thickness of about 4 - 8nm as shown in Fig. 2b.
• Ig of Tinuvin 326 (UV absorber) were dissolved in 19g of IPM (isopropylmyristate) by heating (to a temperature of 60 0 C). 2Og of TEOS were added and the solution was cooled to room temperature.
• the oil phase was homogenized with water solution of CTAC (5g CTAC 29% w/w and 95g RO water) using a high-shear homogenizer (Polytron PT 6100 Kinematica) with dispersing aggregates PT-DA 6045/6 in 3000 rpm for about 5 min in a long neck beaker (200ml).
• the fine emulsion was sheared for lOmin. in M-I lOY microfluidizer processor (microfluidics).
• phenonip (mixture of phenoxyethanol, methylparaben, ethylparaben, propylparaben, butylparaben and isobutylparaben) were dispersed in IPM (16g). 2Og of TEOS were added to the oil phase at room temperature. The oil phase was homogenized
• nano-emulsion was transferred to 400ml beaker equipped with magnetic stirrer. 0.5ml of IM HCl solution was added as catalyst and the nano-emulsion was stirred for 24h.
• An aqueous suspension was prepared using the nanocapsules obtained according to Example 2.
• the aqueous suspension contained 10% w/w of the nanocapsules in water (without surfactants) as a medium.
• the aqueous suspension was found to be stable for 3 months at ambient temperature, with about 10% increase in dlO, d50, and d90 parameters.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Dispersion Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Pharmacology & Pharmacy (AREA)
• Public Health (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Engineering & Computer Science (AREA)
• Life Sciences & Earth Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Veterinary Medicine (AREA)
• Manufacturing Of Micro-Capsules (AREA)
• Medicinal Preparation (AREA)
• Cosmetics (AREA)
• Colloid Chemistry (AREA)
• Catalysts (AREA)
• Silicon Compounds (AREA)

Priority Applications (5)

Applications Claiming Priority (2)

Publications (2)

Family

ID=39414445

Family Applications (1)

Country Status (6)

Cited By (33)

Families Citing this family (20)

Family Cites Families (20)

• 2007
  • 2007-12-12 WO PCT/IL2007/001541 patent/WO2008072239A2/en not_active Ceased
  • 2007-12-12 AU AU2007330996A patent/AU2007330996C1/en not_active Ceased
  • 2007-12-12 BR BRPI0720068-4A2A patent/BRPI0720068A2/pt not_active IP Right Cessation
  • 2007-12-12 JP JP2009540970A patent/JP2010512244A/ja active Pending
  • 2007-12-12 US US12/518,743 patent/US10525433B2/en active Active
  • 2007-12-12 EP EP07849567A patent/EP2104558A2/en not_active Withdrawn
• 2013
  • 2013-08-09 JP JP2013165717A patent/JP2013237051A/ja active Pending

Also Published As

Similar Documents

Legal Events